Inceptive vs Saluda Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
Inceptive designs synthetic RNA molecules for therapeutic applications using deep learning and high-throughput experiments; targets mRNA medicines, RNA-based vaccines, and gene regulation; raised $100M Series A led by Andreessen Horowitz;
About
Inceptive is a Berlin and San Francisco-based biotechnology company founded in 2021 by Jakob Uszkoreit (former senior scientist at Google Brain and co-inventor of the Transformer architecture), Rhiju Das (Stanford RNA biophysicist), and other co-founders. The company is applying deep learning to the problem of RNA design — predicting and engineering synthetic RNA sequences that fold into specific structures and perform specific biological functions, such as encoding therapeutic proteins (mRNA medicines), silencing disease genes (siRNA, antisense), or regulating cellular behavior through aptamers and riboswitches.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
About
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.